Citations

Showing 10 of 108162 citations.

Abstract PO035: Engineered glioblastoma tumor models reveal extracellular matrix signals influence the efficacy of targeted inhibitors
Pedrón, Sara , Sarkaria, Jann N. , Harley, Brendan A.C.

Mayo Clinic

Cancer Research | March 1, 2021 | Volume: 81 | Issue: 5_Supplement | Pages: PO035-PO035

10.1158/1538-7445.tme21-po035 Get It

Abstract Biomaterial-based ex vivo models of healthy and diseased brain tissue are among those tools that may help study the complexity of cerebral tissue to better diagnose, prevent, and treat brain diseases. We have established engineered brain tumor biomaterials based on methacrylamide-functionalized gelatin hydrogels and used microfluidic-forming techniques to generate platforms that combine transitions of biophysical and biomolecular properties found in the glioblastoma tumor microenvironment, from the core to the tumor margins (1). Moreover, this biomaterial approach is able to monitor the response of patient-derived xenograft (PDX) cell populations with different molecular signatures; in particular, we have analyzed the amplified and the constitutively activated vIII mutant EGF receptor. We have also characterized PDX response to targeted inhibitors, such as erlotinib, a tyrosine kinase inhibitor that specifically blocks EGFR (2). Patients with glioblastoma (GBM) exhibit poor survival rates, tied both to the significant intra and interpatient heterogeneity of the tumor as well as the complex signaling pathways underlying malignancy. Spatial and temporal gradients regulate cell proliferation, migration, and differentiation during cancer. Therefore, the use of a microfluidic approach to fabricate patterned biomaterials, have the ability to examine transitions between defined environments (e.g., glioma core, periphery and neural tissue). Cells within these structured materials can be fully analyzed by imaging, secretomic and gene expression analyses. Cell morphology evolved to a more spread shape from low to high crosslinking density of gelatin and hypoxic levels depended on cell concentration. Using patient derived GBM tumor samples we are able to generate a miniaturized tumor tissue analog to examine how the heterogeneities within the tumor microenvironment impact glioma malignant phenotype, growth, and therapeutic efficacy. The ability to manipulate tumor extracellular matrix (ECM) can improve therapeutic outcomes and restrict glioma infiltration. Our in vitro tumor model is able to analyze the relationship between HA and the invasive phenotype of GBM tumor cells. We show that cell growth, motility and proteomic responses of GBM cells within our platform were significantly altered by HA molecular weight in response to a tyrosine kinase inhibitor. These results provide additional insights regarding the importance of extracellular microenvironment in the invasive potential of GBM tumors. We have demonstrated that repeated dosing of erlotinib promotes expression of PDGFRb in EGFR vIII mutant cells and that extracellular HA plays a favorable role in the inhibition of EGFR, through STAT3 deactivation (3). (1) Pedron S et al. (2015), Adv. Mater., 27: 1567; (2) Pedron S. et al. (2017), Adv. Healthcare Mater., 6: 1700529; (3) Pedron S, et al. (2019), Biomaterials, 219: 119371. Citation Format: Sara Pedron, Jann N. Sarkaria, Brendan A.C. Harley. Engineered glioblastoma tumor models reveal extracellular matrix signals influence the efficacy of targeted inhibitors [abstract]. In: Proceedings of the AACR Virtual Special Conference on the Evolving Tumor Microenvironment in Cancer Progression: Mechanisms and Emerging Therapeutic Opportunities; in association with the Tumor Microenvironment (TME) Working Group; 2021 Jan 11-12. Philadelphia (PA): AACR; Cancer Res 2021;81(5 Suppl):Abstract nr PO035.
The spectrum of pediatric scarring alopecia: A retrospective review of 27 patients seen at Mayo Clinic
Imhof, Reese L. , Proffer, Sydney L. , Tolkachjov, Stanislav N. , Torgerson, Rochelle R. , Tollefson, Megha M. , Cantwell, Hafsa M. , Imhof, Reese L

Mayo Clinic

Pediatric Dermatology | March 1, 2021 | Volume: 38 | Issue: 3 | Pages: 580-584

10.1111/pde.14543 | PMID 33644931 Get It

AbstractBackground/ObjectiveThere are few studies examining pediatric scarring alopecia. The objective of this study is to characterize the clinicopathologic findings, comorbidities, and treatment outcomes of pediatric patients with scarring alopecia.MethodsRetrospective review of patients under age 18 diagnosed with scarring alopecia at Mayo Clinic from 01/01/1992 through 02/05/2019.Results27 patients met inclusion criteria with a mean age of 11.2 years and a racial breakdown of 85.2% (23) White, 11.1% (3) Black, and 3.7% (1) Multiracial. Clinical scarring was noted in most (23, 85.2%). Biopsy confirmed the diagnosis in most (24, 88.9%). The most common diagnoses were folliculitis decalvans (6, 22.2%), lichen planopilaris (6, 22.2%), aplasia cutis congenita (4, 14.8%), tinea capitis (4, 14.8%), and morphea (3, 11.1%). Comorbid depression (6, 22.2%) and anxiety (6, 22.2%) were prevalent. Of the patients who received follow‐up, most who pursued treatment achieved stabilization (55.5%) or slowing of progression (27.8%), with 44.4% of those treated experiencing regrowth. Mean time to stabilization in the treated population was 19.6 months. Two patients did not pursue treatment, but received follow‐up and these untreated patients did not experience hair regrowth.ConclusionsMost patients presented with clinically evident primary scarring alopecia. Biopsy may confirm the diagnosis. Active treatment should be pursued, and successful treatment often requires combination therapies. Time to stabilization often takes years. Screening for depression and anxiety should be pursued.
International trends in grant and fellowship funding awarded to women in neurosurgery
Wang, Kimberly , Bhandarkar, Archis R. , Bauman, Megan M. J. , Riviere-Cazaux, Cécile , Rotter, Juliana , Scheitler, Kristen M. , Renfrow, Jaclyn J. , Bauman, Megan , Clarke, Michelle J.

Mayo Clinic

Neurosurgical Focus | March 1, 2021 | Volume: 50 | Issue: 3 | Pages: E5

10.3171/2020.12.focus20846 | PMID 33789231 Get It

OBJECTIVE Metric tracking of grant funding over time for academic neurosurgeons sorted by gender informs the current climate of career development internationally for women in neurosurgery. METHODS Multivariate linear trend analysis of grant funding awarded to neurosurgeons in the NIH and World Research Portfolio Online Reporting Tools Expenditures and Results (RePORTER) was performed. Traveling fellowships for international neurosurgery residents sponsored by the AANS and Congress of Neurological Surgeons (CNS) were also analyzed. RESULTS Within the US, funding awarded to female neurosurgeons has remained static from 2009 to 2019 after adjusting for inflation and overall trends in NIH funding (β = −$0.3 million per year, p = 0.16). Internationally, female neurosurgeons represented 21.7% (n = 5) of project leads for World RePORTER grants. Traveling fellowships are also an important building block for young international female neurosurgeons, of which 7.4% (n = 2) of AANS international traveling fellowships and 19.4% (n = 7) of AANS/CNS pediatrics international traveling fellowships are women. CONCLUSIONS Over the past decade, funding has increased in neurosurgery without a concordant increase in funding awarded to women. Recognition of this trend is essential to focus efforts on research and career development opportunities for women in neurosurgery. Worldwide, female neurosurgeons head one-fifth of the funded project leads and constitute a minority of international traveling fellowships awarded by organized neurosurgery.
Survival outcomes in locally advanced cutaneous squamous cell carcinoma presenting with clinical perineural invasion alone
Hazim, Antonious , Reed, Clay T. , Price, Katharine A. , Foote, Robert L. , Neben-Wittich, M.A. , Jenkins, Sarah M. , Hazim, Antonious Z , Neben-Wittich, Michelle, DeLone, David R. , Daniel, J. , Smith, Carin Y. , Chintakuntlawar, Ashish V.

Mayo Clinic

Head & Neck | March 1, 2021 | Volume: 43 | Issue: 7 | Pages: 1995-2001

10.1002/hed.26661 | PMID 33644935 Get It

AbstractBackgroundCutaneous squamous cell carcinomas (CSCC) involving the head and neck are common, but initial presentation or recurrence limited to the cranial nerves is rare.MethodsWe conducted a retrospective study of 21 patients with clinical perineural invasion (PNI) from CSCC and no measurable disease by RECIST 1.1. Patients treated with radiotherapy or chemoradiotherapy were included.ResultsThe median time from symptom onset until diagnosis was 13.0 months (2.6–83.1). All patients received radiotherapy. Fourteen received concurrent systemic therapy. The median follow‐up time was 30.5 months (1.1–106.0). Ten patients recurred, with the majority being locoregional. The 2‐year overall survival rate was 85%. The median progression‐free survival (PFS) was 21.5 months with an estimated 2‐year PFS of 44.5% (95%CI: 22.3–66.8).ConclusionsCSCCs with clinical PNI alone are difficult to diagnose and can have a long interval between appearance of symptoms and diagnosis. They can successfully be treated with chemoradiotherapy. However, many patients still suffer from locoregional recurrences.
Aspirin and other nonsteroidal anti‐inflammatory drugs, statins and risk of non‐Hodgkin lymphoma
Liebow, Mark , Thompson, Carrie A. , Nowakowski, Grzegorz S. , Call, Timothy G. , Macon, William R. , Cerhan, James R. , Cerhan, James R , Larson, Melissa C. , Kay, Neil E. , Habermann, Thomas M. , Slager, Susan L.

Mayo Clinic

International Journal of Cancer | March 1, 2021 | Volume: 149 | Issue: 3 | Pages: 535-545

10.1002/ijc.33541 | PMID 33644854 Get It

AbstractNon‐steroidal anti‐inflammatory drugs (NSAIDs) and statin drugs may protect against the development of non‐Hodgkin lymphoma (NHL), but data are limited, particularly for NHL subtypes. Furthermore, some in vitro, animal and epidemiologic data suggest there may be a synergistic effect of these two agents, but there has been no test of this hypothesis in NHL. We evaluated the self‐reported use of NSAIDs and statins in a clinic‐based study of 1703 NHL patients and 2199 frequency‐matched controls. Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for potential confounding variables. We observed an inverse association of regular use of low‐dose aspirin with risk of NHL (OR = 0.82; 95% CI 0.70‐0.96) that was stronger with longer duration of use (P < .01). There were no associations for use of regular or extra‐strength aspirin, ibuprofen, other NSAIDs, statins or other cholesterol‐lowering drugs with NHL risk, while an inverse association with COX‐2 inhibitors was equivocal. There was also no interaction of low‐dose aspirin and statins on NHL risk. Inverse associations of similar magnitude to all NHL were observed for regular use of low‐dose aspirin with diffuse large B‐cell, follicular, marginal zone and all other lymphomas, although not all associations were statistically significant. In conclusion, low‐dose aspirin but not regular/extra strength aspirin, other NSAIDs or statin use was associated with lower risk of NHL. Beyond the potential for the primary prevention of NHL, these data also point to a role of anti‐platelet or other effects of low‐dose aspirin in lymphomagenesis that warrant follow‐up.
Integrated Proteomic and Phosphoproteomics Analysis of DKK3 Signaling Reveals Activated Kinase in the Most Aggressive Gallbladder Cancer
Gondkar, Kirti , Joshi, Neha , Pandey, Akhilesh , Kumar, Prashant , Kumar, Prashant , Pandey, Akhilesh , Joshi, Neha S , Sathe, Gajanan , Nair, Bipin G.

Mayo Clinic

Cells | February 28, 2021 | Volume: 10 | Issue: 3 | Pages: 511

10.3390/cells10030511 | PMID 33670899 Get It

DKK3 is a secreted protein, which belongs to a family of Wnt antagonists and acts as a potential tumor suppressor in gallbladder cancer. To further understand its tumor suppressor functions, we overexpressed DKK3 in 3 GBC cell lines. We have employed high-resolution mass spectrometry and tandem mass tag (TMT) multiplexing technology along with immobilized metal affinity chromatography to enrich phosphopeptides to check the downstream regulators. In this study, we reported for the first time the alteration in the phosphorylation of 14 kinases upon DKK3 overexpression. In addition, we observed DKK3 induced hyper phosphorylation of 2 phosphatases: PPP1R12A and PTPRA, which have not been reported previously. Canonical pathway analysis of altered molecules indicated differential enrichment of signaling cascades upon DKK3 overexpression in all the 3 cell lines. Protein kinase A signaling, Sirtuin signaling pathway, and Cell Cycle Control of Chromosomal Replication were observed to be differentially activated in the GBC cell lines. Our study revealed, DKK3 overexpression has differential effect based on the aggressive behavior of the cell lines. This study expands the understanding of DKK3-mediated signaling events and can be used as a primary factor for understanding the complex nature of this molecule.
Hepatorenal Syndrome: A Case Study of Outpatient to Inpatient to Recovery
Chaney, Amanda , Chaney, Amanda J

Mayo Clinic

Clinical Liver Disease | February 28, 2021 | Volume: 17 | Issue: 2 | Pages: 81-84

10.1002/cld.1038 | PMID 33680441 Get It

Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States
Kim, Donghee , Wijarnpreecha, Karn , Sandhu, Keeryth K., Ahmed, Aijaz , Wijarnpreecha, Karn , Kim, Donghee , Cholankeril, George , Ahmed, Aijaz

Mayo Clinic

Liver International | February 28, 2021 | Volume: 41 | Issue: 8 | Pages: 1832-1840

10.1111/liv.14852 | PMID 33641244 Get It

AbstractBackground & AimsNonalcoholic fatty liver disease (NAFLD) has been associated with sarcopenia. However, mortality in the setting of NAFLD‐related sarcopenia remains undefined. We aim to determine the all‐cause and cause‐specific mortality from sarcopenia among adults with NAFLD in the USA.Methods11 065 individuals in the Third National Health and Nutrition Examination Survey were studied and linked mortality through 2015 was analysed. NAFLD was diagnosed based on presence of ultrasonographic hepatic steatosis without other known liver diseases. Sarcopenia was defined as skeletal muscle index determined by bioelectrical impedance analysis. The Cox proportional hazard model was used to assess all‐cause mortality and cause‐specific mortality, and hazard ratio (HR) adjusted for known risk factors.ResultsDuring a median follow‐up of 23 years or more, sarcopenia was associated with increased all‐cause mortality (HR 1.27, 95% confidence interval [CI] 1.11‐1.44). Only in individuals with NAFLD, sarcopenia was associated with a higher risk for all‐cause mortality, while this association was absent in those without NAFLD. Individuals with both sarcopenia and NAFLD had a higher risk for all‐cause mortality (HR 1.28 95% CI 1.06‐1.55) compared with those without sarcopenia and NAFLD. Furthermore, sarcopenia was associated with a higher risk for cancer‐ and diabetes‐related mortality among those with NAFLD. This association was not noted in those without NAFLD.ConclusionIn this nationally representative sample of US adults, sarcopenia was associated with a higher risk for all‐cause, cancer‐ and diabetes‐related mortality in individuals with NAFLD.
Would Women With Solid Organ Transplant Qualify for Triennial Cervical Cancer Screening as Recommended by the American College of Obstetricians and Gynecologists in 2016 and American Society for Colposcopy and Cervical Pathology in 2019?
Long, Margaret E. , Chantigian, Paula D.M., Weaver, Amy L.

Mayo Clinic

Journal of Lower Genital Tract Disease | February 27, 2021 | Volume: 25 | Issue: 2 | Pages: 92-97

10.1097/lgt.0000000000000588 | PMID 33631778 Get It

Objective The aim of the study was to assess the applicability and safety of cervical cancer screening guidelines recommended by the American College of Obstetricians and Gynecologists (2016) and American Society for Colposcopy and Cervical Pathology (2019) for women with solid organ transplants (SOTs). Materials and Methods We analyzed data previously abstracted through December 2015 for 971 women (18–60 y) who received their first SOT at Mayo Clinic (Rochester, MN) from January 17, 1995, through December 31, 2011. Inclusion criteria were initial benign findings on cervical cytology after SOT and at least 1 subsequent cytologic screening. Results Of 415 women whose initial cytologic findings were benign, 310 met inclusion criteria. The cumulative incidence of abnormal cervical cytology among these 310 women was 4.3% (95% CI = 1.9%–6.7%) by 30 months and 11.2% (95% CI = 7.1%–15.4%) by 60 months after their initial benign results. Considering all women with SOT, 68.4% (284/415) had no documented abnormal cytologic findings within 60 months (26 had abnormality; 284 no abnormality; and 105 not assessed). In women with negative tests for human papillomavirus, high-grade squamous intraepithelial lesions were not documented on cytology with variable duration of follow-up. No cervical squamous cell carcinoma was identified. Conclusions Of women with initial benign cervical cytology after SOT, more than two thirds would have been eligible for extended-interval screening. Further study is needed, particularly regarding the role of high-risk human papillomavirus testing.
The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results
Landmark, Cecilie Johannessen , Auvin, Stéphane , Wilmshurst, Jo M. , Johannessen, Svein I. , Trenité, Dorothée Kasteleijn‐Nolst, Wirrell, Elaine , Johannessen Landmark, Cecilie , Potschka, Heidrun , Auvin, Stéphane , Wilmshurst, Jo M , Johannessen, Svein I , Kasteleijn-Nolst Trenité, Dorothée , Wirrell, Elaine C

Mayo Clinic

Epilepsia | February 27, 2021 | Volume: 62 | Issue: 4 | Pages: 857-873

10.1111/epi.16849 | PMID 33638459 Get It

Abstract Developmental and epileptic encephalopathies (DEEs) are among the most challenging of all epilepsies to manage, given the exceedingly frequent and often severe seizure types, pharmacoresistance to conventional antiseizure medications, and numerous comorbidities. During the past decade, efforts have focused on development of new treatment options for DEEs, with several recently approved in the United States or Europe, including cannabidiol as an orphan drug in Dravet and Lennox–Gastaut syndromes and everolimus as a possible antiepileptogenic and precision drug for tuberous sclerosis complex, with its impact on the mammalian target of rapamycin pathway. Furthermore, fenfluramine, an old drug, was repurposed as a novel therapy in the treatment of Dravet syndrome. The evolution of new insights into pathophysiological processes of various DEEs provides possibilities to investigate novel and repurposed drugs and to place them into the context of their role in future management of these patients. The purpose of this review is to provide an overview of these new medical treatment options for the DEEs and to discuss the clinical implications of these results for improved treatment.